JP2025504909A5 - - Google Patents
Info
- Publication number
- JP2025504909A5 JP2025504909A5 JP2024544393A JP2024544393A JP2025504909A5 JP 2025504909 A5 JP2025504909 A5 JP 2025504909A5 JP 2024544393 A JP2024544393 A JP 2024544393A JP 2024544393 A JP2024544393 A JP 2024544393A JP 2025504909 A5 JP2025504909 A5 JP 2025504909A5
- Authority
- JP
- Japan
- Prior art keywords
- binding domain
- binding
- seq
- fusion protein
- triple
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263303481P | 2022-01-26 | 2022-01-26 | |
| US63/303,481 | 2022-01-26 | ||
| US202263417655P | 2022-10-19 | 2022-10-19 | |
| US63/417,655 | 2022-10-19 | ||
| PCT/CA2023/050103 WO2023141713A1 (en) | 2022-01-26 | 2023-01-26 | Immunomodulatory trispecific t cell engager fusion proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025504909A JP2025504909A (ja) | 2025-02-19 |
| JP2025504909A5 true JP2025504909A5 (https=) | 2026-01-29 |
Family
ID=87469895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024544393A Pending JP2025504909A (ja) | 2022-01-26 | 2023-01-26 | 免疫調節性三重特異性ｔ細胞エンゲージャー融合タンパク質 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250019440A1 (https=) |
| EP (1) | EP4469488A4 (https=) |
| JP (1) | JP2025504909A (https=) |
| KR (1) | KR20240137058A (https=) |
| AU (1) | AU2023212483A1 (https=) |
| CA (1) | CA3247443A1 (https=) |
| IL (1) | IL314169A (https=) |
| MX (1) | MX2024009165A (https=) |
| WO (1) | WO2023141713A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023312397A1 (en) * | 2022-07-29 | 2025-03-13 | Zymeworks Bc Inc. | Multivalent and bispecific antibody constructs and methods of use thereof |
| CA3266966A1 (en) * | 2022-10-19 | 2024-04-25 | Zymeworks Bc Inc. | TRIVALENT AND TRISPECIFIC ANTIBODY CONSTRUCTIONS AND THEIR METHODS OF USE |
| WO2025085862A2 (en) * | 2023-10-20 | 2025-04-24 | BioNTech SE | Multispecific t cell engagers compositions and methods of use thereof |
| WO2025122988A2 (en) * | 2023-12-08 | 2025-06-12 | Aarvik Therapeutics, Inc. | Engineered antibodies and immunoconjugates and methods of use |
| TW202600597A (zh) * | 2024-03-04 | 2026-01-01 | 加拿大商酵活英屬哥倫比亞有限公司 | 靶向ｄｌｌ３之三特異性抗體構築體及其使用方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3827019A1 (en) * | 2018-07-24 | 2021-06-02 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| EP3816185A1 (en) * | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
| TWI908779B (zh) * | 2020-03-17 | 2025-12-21 | 美商西雅圖免疫公司 | 引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法 |
| WO2022016270A1 (en) * | 2020-07-20 | 2022-01-27 | Zymeworks Inc. | Fusion proteins comprising a ligand-receptor pair and a biologically functional protein |
-
2023
- 2023-01-26 IL IL314169A patent/IL314169A/en unknown
- 2023-01-26 JP JP2024544393A patent/JP2025504909A/ja active Pending
- 2023-01-26 AU AU2023212483A patent/AU2023212483A1/en active Pending
- 2023-01-26 CA CA3247443A patent/CA3247443A1/en active Pending
- 2023-01-26 EP EP23745768.4A patent/EP4469488A4/en active Pending
- 2023-01-26 KR KR1020247027803A patent/KR20240137058A/ko active Pending
- 2023-01-26 WO PCT/CA2023/050103 patent/WO2023141713A1/en not_active Ceased
-
2024
- 2024-07-24 MX MX2024009165A patent/MX2024009165A/es unknown
- 2024-07-24 US US18/783,028 patent/US20250019440A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025504909A5 (https=) | ||
| JP2021524267A5 (https=) | ||
| CN119505009A (zh) | 针对cldn18.2和cd3的抗体构建体 | |
| JP2023509448A5 (https=) | ||
| JP2018502050A5 (https=) | ||
| IL268620B1 (en) | Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment | |
| JP7399852B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP2021508469A5 (https=) | ||
| JP2022551081A5 (https=) | ||
| JP2021510521A5 (https=) | ||
| CN115397852B (zh) | 工程化抗il-2抗体 | |
| CN108271376A (zh) | 结合dll3和cd3的双特异性抗体构建体 | |
| IL292780A (en) | A new 4-1bbl trimer containing antigen-binding molecules | |
| JP2021528973A5 (https=) | ||
| WO2012020622A1 (ja) | ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用 | |
| JP2012531212A5 (https=) | ||
| JP2020515277A5 (https=) | ||
| CN110719918A (zh) | 靶向至少cd3和hsa的异源二聚体多特异性抗体形式 | |
| JP2023506750A5 (https=) | ||
| WO2019196309A1 (zh) | 抗pd-l1抗体及其用途 | |
| CN113461824A (zh) | 一种构建多特异性抗体的平台 | |
| JP2024509910A5 (https=) | ||
| CN108164600A (zh) | 一种抗gpc3抗体及其制备方法和用途 | |
| JP2025508317A5 (https=) | ||
| JP2024516098A5 (https=) |